Results 51 to 60 of about 3,549 (185)
Biopharmaceuticals for Cancer Treatment: An Update
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath +6 more
wiley +1 more source
Frontiers in Oncology, 2023 BackgroundA chemotherapy of rituximab, fludarabine and cyclophosphamide (R-FC) has been accepted as a promising frontline chemotherapy in selected patients with chronic lymphocytic leukemia (CLL).
Youngwoo Jeon +15 more
doaj +1 more source
The incidence and timing of leukocyte overshoot after pegfilgrastim administration
, 2018 Introduction Pegfilgrastim is a PEGylated formulation of filgrastim with a long half-life. It is highly convenient and less burdensome for patients. However, white blood cell count may temporarily increase after administration; in particular, a leukocyte
Michio Kimura +7 more
core +1 more source
Primary Prophylaxis Lapelga® in Early Breast Cancer: A Real-World Experience
Current Oncology, 2023 Background: Lapelga® was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category.
Fahad Khan +3 more
doaj +1 more source
An Unusual Case Presentation on Docetaxel Induced Lung Injury
Clinical Case Reports, Volume 14, Issue 4, April 2026.ABSTRACT Docetaxel can rarely cause acute interstitial lung injury early in therapy. New‐onset cough, fever, or dyspnea after chemotherapy should prompt immediate evaluation, exclusion of infection, and high‐resolution CT imaging. Early drug withdrawal and timely corticosteroid therapy can result in rapid clinical recovery and prevent serious morbidity.
Soorej Balan Kaliyath +7 more
wiley +1 more source
Pegfilgrastim enhances the antitumor effect of therapeutic monoclonal antibodies
, 2016 International audienceTherapeutic monoclonal antibodies (mAbs) exert antitumor activity through various mechanisms including apoptotic signalization, complement dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis ...
Tredan, Olivier +6 more
core +1 more source
Case Reports in Oncology, 2023 Introduction: Granulocyte colony-stimulating factor (G-CSF), including pegfilgrastim, increases the peripheral blood leukocyte count and is widely used in clinical practice in combination with cytotoxic chemotherapy.
Takanori Ito +7 more
doaj +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau +62 more
wiley +1 more source
Pegfilgrastim in pediatric cancer patients
, 2005 Chemotherapy-induced neutropenia is a major dose-limiting side effect of intensive chemotherapy in cancer patients. Recently, pegfilgrastim (a product with a long half-life, resulting in once-per-cycle dosage) was introduced to prevent neutropenia in ...
de Bont, ESJM +5 more
core +1 more source
Frontiers in Pharmacology, 2017 Background: Lipegfilgrastim (Lonquex®) has demonstrated to be non-inferior to pegfilgrastim (Neulasta®) in reducing the duration of severe neutropenia (SN) in patients with stage II−IV breast cancer.
Esse I. H. Akpo +3 more
doaj +1 more source